Higher PD-1/Tim-3 expression on IFN-γ+ T cells is associated with poor prognosis in patients with acute myeloid leukemia

References

• Daver N, Alotaibi AS, Bücklein V, Subklewe M. T-cell-based immunotherapy of acute myeloid leukemia: current concepts and future developments. Leukemia. 2021 05 07;35(7):1843–9. doi:10.1038/s41375-021-01253-x.
   PubMed Web of Science ®Google Scholar
• Wang M, Bu J, Zhou M, Sido J, Lin Y, Liu G, Lin Q, Xu X, Leavenworth JW, Shen E. CD8(+)T cells expressing both PD-1 and TIGIT but not CD226 are dysfunctional in acute myeloid leukemia (AML) patients. Clin Immunol. 2018;190:64–73. 2017 09 13. doi:10.1016/j.clim.2017.08.021.
   PubMed Web of Science ®Google Scholar
• Li Z, Philip M, Ferrell PB. Alterations of T-cell-mediated immunity in acute myeloid leukemia. Oncogene. 2020 03 05;39(18):3611–3619. doi:10.1038/s41388-020-1239-y.
   PubMed Web of Science ®Google Scholar
• Huang S, Liang C, Zhao Y, Deng T, Tan J, Zha X, Li Y, Chen S. Increased TOX expression concurrent with PD-1, Tim-3, and CD244 expression in T cells from patients with acute myeloid leukemia. Cytometry B Clin Cytom. 2022;102(2):143–152. 2021 12 17. doi:10.1002/cyto.b.22049.
   PubMed Web of Science ®Google Scholar
• Chen X, Du Y, Lin X, Qian Y, Zhou T, Huang Z, CD4+CD25+ regulatory T cells in tumor immunity. Int Immunopharmacol. 2016 03 20;34:244–249. doi:10.1016/j.intimp.2016.03.009.
   PubMed Web of Science ®Google Scholar
• Binder S, Luciano M, Horejs-Hoeck J. The cytokine network in acute myeloid leukemia (AML): a focus on pro- and anti-inflammatory mediators. Cytokine Growth Factor Rev. 2018 09 06;43:8–15. doi:10.1016/j.cytogfr.2018.08.004.
   PubMed Web of Science ®Google Scholar
• Luciano M, Krenn PW, Horejs-Hoeck J. The cytokine network in acute myeloid leukemia. Front Immunol. 2022 10 18;13:1000996. doi:10.3389/fimmu.2022.1000996.
   PubMed Web of Science ®Google Scholar
• Tan J, Chen S, Lu Y, Yao D, Xu L, Zhang Y, Yang L, Chen J, Lai J, Yu Z, et al. Higher PD-1 expression concurrent with exhausted CD8+ T cells in patients with de novo acute myeloid leukemia. Chin J Cancer Res. 2017 11 17;29(5):463–470. doi:10.21147/j.issn.1000-9604.2017.05.11.
   PubMed Web of Science ®Google Scholar
• Tan J, Huang S, Huang J, Yu Z, Chen Y, Lu Y, Li Y, Chen S. Increasing Tim-3+CD244+, Tim-3+CD57+, and Tim-3+PD-1+ T cells in patients with acute myeloid leukemia. Asia Pac J Clin Oncol. 2020 02 08;16(3):137–141. doi:10.1111/ajco.13304.
   PubMed Web of Science ®Google Scholar
• Chen Y, Tan J, Huang S, Huang X, Huang J, Chen J, Yu Z, Lu Y, Weng J, Du X, et al.Higher frequency of the CTLA-4+LAG-3 + T-cell subset in patients with newly diagnosed acute myeloid leukemia. Asia Pac J Clin Oncol. 2020;16(2):e12–e18. 2019 10, 16. doi:10.1111/ajco.13236.
   PubMed Web of Science ®Google Scholar
• Zhao Y, Liao P, Huang S, Deng T, Tan J, Huang Y, Zhan H, Li Y, Chen S, Zhong L. Increased TOX expression associates with exhausted T cells in patients with multiple myeloma. Exp Hematol Oncol. 2022;11(1):12. 2022 03, 6. doi:10.1186/s40164-022-00267-0.
   PubMed Web of Science ®Google Scholar
• Chen C, Li Y. Predictive value of co-expression patterns of immune checkpoint molecules for clinical outcomes of hematological malignancies. Chin J Cancer Res. 2023 07 13;35(3):245–251. doi:10.21147/j.issn.1000-9604.2023.03.04.
   PubMed Web of Science ®Google Scholar
• Huang J, Tan J, Chen Y, Huang S, Xu L, Zhang Y, Lu Y, Yu Z, Chen S, Li Y. A skewed distribution and increased PD-1+Vβ+CD4+/CD8+ T cells in patients with acute myeloid leukemia. J Leukoc Biol. 2019 05 29;106(3):725–732. doi:10.1002/JLB.MA0119-021R.
   PubMed Web of Science ®Google Scholar
• Abbas HA, Hao D, Tomczak K, Barrodia P, Im JS, Reville PK, Alaniz Z, Wang W, Wang R, Wang F, et al. Single cell T cell landscape and T cell receptor repertoire profiling of AML in context of PD-1 blockade therapy. Nat Commun. 2021 10, 20;12(1):6071. doi:10.1038/s41467-021-26282-z.
   PubMed Web of Science ®Google Scholar
• Williams KM. Checkpoint-blocked T cells checkmate AML. Blood. 2021 06 11;137(23):3155–3156. doi:10.1182/blood.2021011497.
   PubMed Web of Science ®Google Scholar
• Hao F, Sholy C, Wang C, Cao M, Kang X. The role of T cell immunotherapy in acute myeloid leukemia. Cells. 2021 12 25;10(12):3376. doi:10.3390/cells10123376.
   PubMed Web of Science ®Google Scholar
• Daver N, Garcia-Manero G, Basu S, Boddu PC, Alfayez M, Cortes JE, Konopleva M, Ravandi-Kashani F, Jabbour E, Kadia T, et al. Efficacy, safety, and biomarkers of response to azacitidine and nivolumab in relapsed/refractory acute myeloid leukemia: a nonrandomized, open-label, phase II study. Cancer Discov. 2019 11 10;9(3):370–383. doi:10.1158/2159-8290.Cd-18-0774.
   PubMed Web of Science ®Google Scholar
• Ravandi F, Assi R, Daver N, Benton CB, Kadia T, Thompson PA, Borthakur G, Alvarado Y, Jabbour EJ, Konopleva M, et al. Idarubicin, cytarabine, and nivolumab in patients with newly diagnosed acute myeloid leukaemia or high-risk myelodysplastic syndrome: a single-arm, phase 2 study. Lancet Haematol. 2019 08 12;6(9):e480–e488. doi:10.1016/S2352-3026(19)30114-0.
   PubMed Web of Science ®Google Scholar
• Koyama S, Akbay EA, Li YY, Herter-Sprie GS, Buczkowski KA, Richards WG, Gandhi L, Redig AJ, Rodig SJ, Asahina H, et al. Adaptive resistance to therapeutic PD-1 blockade is associated with upregulation of alternative immune checkpoints. Nat Commun. 2016 02 18;7(1):10501. doi:10.1038/ncomms10501.
   PubMed Web of Science ®Google Scholar
• Wu K, Feng J, Xiu Y, Li Z, Lin Z, Zhao H, Zeng H, Xia W, Yu L, Xu B, Vδ2 T cell subsets, defined by PD-1 and TIM-3 expression, present varied cytokine responses in acute myeloid leukemia patients. Int Immunopharmacol. 2020 01 20;80:106122. doi:10.1016/j.intimp.2019.106122.
   PubMed Web of Science ®Google Scholar
• Liao D, Wang M, Liao Y, Li J, Niu T, A review of efficacy and safety of checkpoint inhibitor for the treatment of acute myeloid leukemia. Front Pharmacol. 2019 06 28;10:609. doi:10.3389/fphar.2019.00609.
   PubMed Web of Science ®Google Scholar
• Yang X, Ma L, Zhang X, Huang L, Wei J. Targeting PD-1/PD-L1 pathway in myelodysplastic syndromes and acute myeloid leukemia. Exp Hematol Oncol. 2022 03 04;11(1):11. doi:10.1186/s40164-022-00263-4.
   PubMed Web of Science ®Google Scholar
• Abedi Kiasari B, Abbasi A, Ghasemi Darestani N, Adabi N, Moradian A, Yazdani Y, Sadat Hosseini G, Gholami N, Janati S, Combination therapy with nivolumab (anti-PD-1 monoclonal antibody): a new era in tumor immunotherapy. Int Immunopharmacol. 2022 11 05;113:109365. doi:10.1016/j.intimp.2022.109365.
   PubMed Web of Science ®Google Scholar
• Tan J, Yu Z, Huang J, Chen Y, Huang S, Yao D, Xu L, Lu Y, Chen S, Li Y. Increased PD-1+Tim-3+ exhausted T cells in bone marrow may influence the clinical outcome of patients with AML. Biomark Res. 2020 02 23;8(1):6. doi:10.1186/s40364-020-0185-8.
   PubMed Web of Science ®Google Scholar
• Kong Y, Zhang J, Claxton DF, Ehmann WC, Rybka WB, Zhu L, Zeng H, Schell TD, Zheng H. PD-1(hi)TIM-3(+) T cells associate with and predict leukemia relapse in AML patients post allogeneic stem cell transplantation. Blood Cancer J. 2015 08 01;5(7):e330. doi:10.1038/bcj.2015.58.
   PubMedGoogle Scholar
• Zhou Q, Munger ME, Veenstra RG, Weigel BJ, Hirashima M, Munn DH, Murphy WJ, Azuma M, Anderson AC, Kuchroo VK, et al. Coexpression of Tim-3 and PD-1 identifies a CD8+ T-cell exhaustion phenotype in mice with disseminated acute myelogenous leukemia. Blood. 2011 03 10;117(17):4501–4510. doi:10.1182/blood-2010-10-310425.
   PubMed Web of Science ®Google Scholar
• De Mello RA, Zhu JH, Iavelberg J, Potim AH, Simonetti D, Silva Jr JA, Castelo-Branco P, Pozza DH, Tajima CC, Tolia M, et al. Current and future aspects of TIM-3 as biomarker or as potential targeted in non-small cell lung cancer scope: is there a role in clinical practice? Transl Lung Cancer Res. 2020;9(6):2311–2314. doi:10.21037/tlcr-20-625.
   PubMed Web of Science ®Google Scholar
• Kalbasi A, Ribas A. Tumour-intrinsic resistance to immune checkpoint blockade. Nat Rev Immunol. 2020;20(1):25–39. 2019 10, 2. doi:10.1038/s41577-019-0218-4.
   PubMed Web of Science ®Google Scholar
• Topalian SL, Drake CG, Pardoll DM. Immune checkpoint blockade: a common denominator approach to cancer therapy. Cancer Cell. 2015;27(4):450–461. 2015 04, 11. doi:10.1016/j.ccell.2015.03.001.
   PubMed Web of Science ®Google Scholar
• Corradi G, Bassani B, Simonetti G, Sangaletti S, Vadakekolathu J, Fontana MC, Pazzaglia M, Gulino A, Tripodo C, Cristiano G, et al. Release of IFNγ by acute myeloid leukemia cells remodels bone marrow immune microenvironment by inducing regulatory T cells. Clin Cancer Res. 2022 03 30;28(14):3141–3155. doi:10.1158/1078-0432.Ccr-21-3594.
   PubMed Web of Science ®Google Scholar
• Sun YX, Kong HL, Liu CF, Yu S, Tian T, Ma D-X, Ji C-Y. The imbalanced profile and clinical significance of T helper associated cytokines in bone marrow microenvironment of the patients with acute myeloid leukemia. Hum Immunol. 2014;75(2):113–118. 2013 11, 26. doi:10.1016/j.humimm.2013.11.014.
   PubMed Web of Science ®Google Scholar
• Jiang W, He Y, He W, Wu G, Zhou X, Sheng Q, Zhong W, Lu Y, Ding Y, Lu Q, et al. Exhausted CD8+T cells in the tumor immune microenvironment: new pathways to therapy. Front Immunol. 2020;11:622509. 2021 02, 27. doi:10.3389/fimmu.2020.622509.
   PubMed Web of Science ®Google Scholar
• Abbas HA, Alaniz Z, Mackay S, Cyr M, Zhou J, Issa GC, Alfayez M, Matthews J, Kornblau SM, Jabbour E, et al. Single-cell polyfunctional proteomics of CD4 cells from patients with AML predicts responses to anti–PD-1–based therapy. Blood Adv. 2021 09 24;5(22):4569–4574. doi:10.1182/bloodadvances.2021004583.
   PubMed Web of Science ®Google Scholar
• Rezaei M, Tan J, Zeng C, Li Y, Ganjalikhani-Hakemi M, TIM-3 in Leukemia; Immune Response and Beyond. Front Oncol. 2021 10 19;11:753677. doi:10.3389/fonc.2021.753677.
   PubMedGoogle Scholar
• Hong J, Xia L, Huang Z, Yuan X, Liang X, Dai J, Wu Z, Liang L, Ruan M, Long Z, et al. TIM-3 expression level on AML blasts correlates with presence of core binding factor translocations rather than clinical outcomes. Front Oncol. 2022 05 03;12:879471. doi:10.3389/fonc.2022.879471.
   PubMed Web of Science ®Google Scholar
• Gonçalves Silva I, Yasinska IM, Sakhnevych SS, Fiedler W, Wellbrock J, Bardelli M, Varani L, Hussain R, Siligardi G, Ceccone G, et al. 2017 07 29. The Tim-3-galectin-9 secretory pathway is involved in the immune escape of human acute myeloid leukemia cells. EBioMedicine. 22:44–57. doi:10.1016/j.ebiom.2017.07.018.
   PubMed Web of Science ®Google Scholar
• Zhong M, Gao R, Zhao R, Huang Y, Chen C, Li K, Yu X, Nie D, Chen Z, Liu X, et al. BET bromodomain inhibition rescues PD-1-mediated T-cell exhaustion in acute myeloid leukemia. Cell Death Disease. 2022 08 03;13(8):671. doi:10.1038/s41419-022-05123-x.
   PubMed Web of Science ®Google Scholar
• Wu M, Huang Q, Xie Y, Wu X, Ma H, Zhang Y, Xia Y. Improvement of the anticancer efficacy of PD-1/PD-L1 blockade via combination therapy and PD-L1 regulation. J Hematol Oncol. 2022 03 14;15(1):24. doi:10.1186/s13045-022-01242-2.
   PubMed Web of Science ®Google Scholar
• Monney L, Sabatos CA, Gaglia JL, Ryu A, Waldner H, Chernova T, Manning S, Greenfield EA, Coyle AJ, Sobel RA, et al. Th1-specific cell surface protein Tim-3 regulates macrophage activation and severity of an autoimmune disease. Nature. 2002 02 02;415(6871):536–541. doi:10.1038/415536a.
   PubMed Web of Science ®Google Scholar
• Rahimi Kalateh Shah Mohammad G, Ghahremanloo A, Soltani A, Fathi E, Hashemy SI. Cytokines as potential combination agents with PD-1/PD-L1 blockade for cancer treatment. J Cell Physiol. 2020 01 24;235(7–8):5449–5460. doi:10.1002/jcp.29491.
   PubMed Web of Science ®Google Scholar